



Attorney Ref: 356A PCT/USC1

1632
#3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Cerasoli

Serial No.: 10/087,286

Filed : March 1, 2002

For : *Expression of Proteins for treating Asthma Via
Ligand Mediated Expression of Their Encoding Genes*

Art Unit: 1632

Examiner: ----

Assistant Commissioner for Patents
Washington, DC 20231

May 30, 2002

RECEIVED
JUN 06 2002
TECH CENTER 1600/2900

Information Disclosure Statement Under 37 CFR §1.97(B)

Applicants and their agents/attorneys are aware of the following publications and information, and in accordance with 37 C.F.R. § 1.97 and § 1.98, wish to make them of record. Form PTO-1449 and copies of each publication are enclosed, or are of record in the parent case, U.S.S.N. 09/367,170, filed August 9, 1999.

The Examiner is respectfully requested to initial the space adjacent to each documents on the PTO-1449 form and return a copy of the PTO-1449 form to confirm that these documents have been considered by the Examiner and made of record in this application.

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, Applicants understand the Examiner will make an independent evaluation of the cited publications.

No additional costs are believed to be due in connection with the filing of this disclosure. However, please charge any necessary fees to our Deposit Account No. 01-2315. Should there be any questions after review of this paper, the Examiner is invited to contact the undersigned at (617) 494-0400 x266.

Respectfully submitted,

David L. Bernstein, Reg No. 31,235
ARIAD Pharmaceuticals, Inc.
26 Landsdowne Street
Cambridge, MA 02139
Telephone: 617-494-0400 Ext. 266
Facsimile: 617-494-020

I hereby certify that this paper is being deposited with the United States Postal Service via First Class Mail under 37 CFR 1.08 on the date indicated above and is addressed to Assistant Commissioner for Patents, Washington, DC 20231
Date May 30, 2002

Signed

Sue Wilson



Form PTO-1449 (Modified) LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO.: ARIAD 356A PCT/USC1	SERIAL NO.: 10/087,286
	APPLICANT: Cerasoli	
	FILING DATE: 03/01/02	GROUP: ----

U.S. PATENT DOCUMENTS

Exam Init	Ref Des	Document No.	Date	Name	Class	Sub Class	Filing Date
	*	5,830,462	11/3/98	Crabtree et al.	424	93.21	6/7/95
	*	5,266,312	11/30/93	Leung et al.	424	85.5	1/27/92
	*	5,464,758	11/7/95	Gossen et al.	435	69.1	6/14/93

FOREIGN PATENT DOCUMENTS

Exam Init	Ref Des	Document No.	Date	Name	Class	Sub Class	Filing Date
	*	WO 96/41865	12/27/96	Clackson et al.			
	*	WO 96/00006	1/4/96	Billiar et al			
	*	WO 94/17773	8/18/94	Goldman et al.			
	*	WO 94/27640	12/8/94	Ward et al.			

OTHER ART

Author, Title, Date, Publication, Pertinent Pages

		No et al., (1996) Proc Natl Acad Sci USA 93:3346-3351.
		Gavett et al., (1995) J. Experimental Medicine 182:1527-1536.
	✓	Xing et al., (1997) Gene Therapy 4:140-149.
	✓	Qin et al., (1997) Human Gene Therapy 8:1365-1374.
	✓	Demoly et al., (1997) Gene Therapy 4:507-516.
	✓	Bellon et al., (1997) Human Gene Therapy 8:15-25.
	✓	Rubenstein et al., (1997) Gene Therapy 4:384-392.
	✓	Conrad et al., (1996) Gene Therapy 3:658-668.
	✓	Sene et al., Human Gene Therapy 1995 Dec; 6(12):1587-1593.
	✓	Janssens et al., J. Clin Invest 1996 Jul 15; 98(2):317-324.
	✓	Anderson, W.F., Nature. 1998 April 30; 392(Suppl):25-30.
	✓	Yao et al., Nature. 1993 Dec 2; 366:476-479.
	✓	Verma & Somia, Nature. 1997 Sept 18; 389: 239-242.
	✓	Disease Weekly Plus. 1997 Aug 18; pg 15.
	✓	Wade, N., New York Times. 1999 Feb 23.
	Will send separately	Lancet, March 25, 1995; Vol 345, pp 739-740.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in the parent case, U.S.S.N. 09/367,170, filed 08/09/1999 and relied upon for an earlier filing date under 35 U.S.C. 120.

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.